A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1 Multicenter, Open-label, Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Antitumor Activity of MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tavolimab (Primary) ; Tremelimumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 25 Apr 2023 to 29 Nov 2023.
    • 20 Oct 2017 Planned primary completion date changed from 14 Aug 2020 to 22 Mar 2021.
    • 22 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top